Gilead CEO Daniel ODay on acquisition of cancer drugmaker Immunomedics

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=2WOZmgrmEX8

Gilead Sciences will acquire biotech company Immunomedics in a $21 billion deal that will expand Gilead's availability of cancer treatments, the companies announced on Sunday. Daniel O'Day, Gilead chairman and CEO, joins Squawk Box to discuss. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi • » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision • » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC • » Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic • • Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide. • • Connect with CNBC News Online • Get the latest news: http://www.cnbc.com/ • Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC • Follow CNBC News on Facebook: https://cnb.cx/LikeCNBC • Follow CNBC News on Twitter: https://cnb.cx/FollowCNBC • Follow CNBC News on Instagram: https://cnb.cx/InstagramCNBC • • For info on the best credit cards go to CNBC Select: • https://www.cnbc.com/select/best-cred... • #CNBC • #CNBCTV

#############################

New on site